Byondis B.v.

This first-in-human trial tests BYON4413, an antibody-drug conjugate designed to target and kill cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS). The study involves 16 participants and aims to check safety, how th…

This early-stage trial tests a new lab-made antibody called BYON4228, alone or with the cancer drug rituximab, in 17 people with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to check safety and find the right dose. It's the first time this drug is being tested …

This early-phase trial tests a new antibody called BYON4228, given alone or with the immunotherapy drug pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study includes only 7 participants and aims to check safety, side effect…